Aclaris Therapeutics, Inc.
ACRS
$6.18
$0.162.66%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -18.39% | 54.13% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -18.39% | 54.13% | |||
| Cost of Revenue | 11.89% | -3.37% | |||
| Gross Profit | -15.80% | 7.81% | |||
| SG&A Expenses | -10.31% | 20.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.70% | 2.37% | |||
| Operating Income | -7.87% | 0.64% | |||
| Income Before Tax | -8.48% | -0.15% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -8.48% | -0.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.48% | -0.15% | |||
| EBIT | -7.87% | 0.64% | |||
| EBITDA | -7.87% | 0.60% | |||
| EPS Basic | 2.08% | 4.65% | |||
| Normalized Basic EPS | 3.43% | 2.63% | |||
| EPS Diluted | 2.08% | 4.65% | |||
| Normalized Diluted EPS | 3.43% | 2.63% | |||
| Average Basic Shares Outstanding | 10.81% | 5.01% | |||
| Average Diluted Shares Outstanding | 10.81% | 5.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||